Tumor Biology

, Volume 35, Issue 7, pp 6879–6886 | Cite as

Serum Zta antibody of Epstein–Barr virus exerts potential function in the diagnosis of nasopharyngeal cancer

  • Xiaoyan Zhang
  • Yun Zhang
  • Yunqiang Nie
  • Shoufeng Wang
  • Yanlin Chen
  • Dezhong Sun
Research Article


The diagnosis of nasopharyngeal cancer (NPC) remains a clinical challenge. Many studies have assessed the diagnostic potential of Zta antibody of the Epstein–Barr virus (EBV) in NPC patients but with controversial results. This study aims to summarize the overall diagnostic performance of EBV Zta antibody in NPC. Based on a comprehensive search of the Pubmed and Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wanfang Databases and China Citation Databases, we identified outcome data from all articles estimating diagnostic accuracy of EBV Zta antibody for NPC. A summary estimation for sensitivity, specificity, and other diagnostic indexes were pooled using a bivariate model. The overall measure of accuracy was calculated using summary receiver operating characteristic curve and the area under curve (AUC) was calculated. According to our inclusion criteria, 17 studies with 11,822 subjects (1,645 NPC cases, 10,177 controls) were included. The summary estimates were: sensitivity 0.87 (95 % confidence interval [CI] = 0.86–0.89), specificity 0.94 (95 % CI = 0.93–0.94), positive likelihood ratio 8.05 (95 % CI = 5.59–11.59), negative likelihood ratio 0.16 (95 % CI = 0.12–0.21), diagnostic odds ratio 52.93 (95 % CI = 29.95–93.56), the AUC and Q* index were 0.9352 and 0.8714, respectively. In conclusion, serum EBV Zta had a better diagnostic performance for NPC. Further studies should be performed to confirm our findings.


Nasopharyngeal cancer Epstein–Barr virus Zta Diagnosis Meta-analysis 


Conflicts of interests



  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA. Cancer J Clin. 2002;55:74–108.CrossRefGoogle Scholar
  2. 2.
    Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765–77.CrossRefPubMedGoogle Scholar
  3. 3.
    O'Neil JD, Owen TJ, Wood VH, Date KL, Valentine R, Chukwuma MB, et al. Epstein–Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 2008;89:2833–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17:1–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Old LJ, Boyse EA, Oettgen HF, de Harven E, Geering G, Williamson B, et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 1966;56(6):1699–740.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Yip TT, Ngan RK, Lau WH, et al. A possible prognostic role of immunoglobulin G antibody against recombinant Epstein Barr virus BZLF1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer. 1994;74:2414–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Cheng HM, Foong YT, AbuSamah AJ, et al. Linear epitopes of the replication activator protein of Epstein Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma. Cancer Immunol Immunother. 1995;40:251–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Teertstra HJ, Loo CE, van den Bosch MA, et al. Breast tomosynthesis in clinical practice: initial results. Eur Radiol. 2010;20:16–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Joab I, Nicolas JC, Schwaab G, et al. Detection of anti-Epstein Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer. 1991;48(5):647–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Zeng Y, Nicolas JC, Schwaab G, et al. Detection of ZE BRA antibody in sera from patients with nasopharyngeal carcinoma infectious mononuc1eosis and Burkitt lymphoma. Bingdu Xuebao. 1992;8(3):218–22.Google Scholar
  11. 11.
    Li D, Zeng Y, Cochet C, et al. Detection of IgG/ZEBRA antibodies in sera from patients with nas0pharyngeal carcinoma by ELISA methods. Bingdu Xuebao. 1994;10(1):78–80.Google Scholar
  12. 12.
    Cao SM, Huang TB, Jian SW. The singnificance of EB virus ZEBRA/IgG in early diagnosis and prognosis of nasopharyngeal carcinoma (NPC). Aizheng. 1998;17(4):4–8.Google Scholar
  13. 13.
    Dardari R, Khyatti M, Benider A, et al. Antibodies to the Epstein–Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma [J]. Int J Cancer. 2000;86(1):71–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheng WM, Chen GX, Chen HI, et al. Assessment of nasopharyngeal carcinoma risk by EB virus antibody profile. Zhonghua Zhongliu Zazhi. 2002;24(6):45–7.Google Scholar
  15. 15.
    Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 2003;105(5):706–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Gu YI, Zhang CQ, Wu ZB, et al. Study on sero diagnosis of nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein Barr virus antigens. Aizheng. 2003;22(9):903–6.PubMedGoogle Scholar
  17. 17.
    Cheng WM, Ji MF, Li XL. Screening out nasopharyngeal carcinoma by two-stage ELISA for EB virus. Zhongguo Mianyixue Zazhi. 2003;19(12):834–6.Google Scholar
  18. 18.
    Zhang XM, Zhong JM, Tang MZ, et al. Comparison of IgA/VCA,IgA/EA,IgG/EA in immunoenzyme methods and ZEBRA EI ISA in early diagnosis of nasopharyngeal carcinoma. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 2006;20(3):263–5.PubMedGoogle Scholar
  19. 19.
    Zheng YM, Tang MZ, Li J, et al. Detection of EB virus ZEBRA/IgG antibody in nasopharyngeal carcinoma serum diagnosis. Huaxia Yixue. 2006;19(6):1092–3.Google Scholar
  20. 20.
    Ren J, Zhang XM, Zhang XG, et al. Studies on antibody response to recombinant Rta protein in patient with nasopharyngeal carcinoma. Zhonghua Weishengwuxue He Mianyixue Zazhi. 2006;26(11):1057–9.Google Scholar
  21. 21.
    Hu WW, Zong YS, Li FP, et al. Comparison of 6 antibody assays detecting Epstein-Barr virus for sero diagnosis of nasopharyngeal carcinoma. Zhongguo Zhongliu Linchuang. 2006;33(14):795–8.Google Scholar
  22. 22.
    Cheng WM, Ji MF, Li X, et al. Analysis of serum levels of antibodies against EBV EBNA1 and EB Zta in individuals in a nasopharyngeal carcinoma clan who have non nasopharyngeal carcinoma. Zhongguo Zhongliu Linchuang. 2007;34(21):1238–40.Google Scholar
  23. 23.
    Yi X, Wu YY, Xie Y, et al. Antibody response to recombinant Epstein–Barr virus Zta protein in patients with nasopharyngeal carcinoma. Guangxi Yike Daxue Xuebao. 2007;24(3):365–7.Google Scholar
  24. 24.
    Liang YJ, Zong YS, Gu YI, et al. Application of enzyme-linked immunosorbent assay to the serological diagnosis of nasopharyngea1 carcinoma. Shiyong Yixue Zazhi. 2008;24(17):3055–8.Google Scholar
  25. 25.
    Jiang SQ, Liu Q. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of naspharyngea1 carcinoma. Aizheng. 2009;28(2):213–6.Google Scholar
  26. 26.
    Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ Br Med J. 1997;315:980–8.CrossRefGoogle Scholar
  27. 27.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Tian JH. Systematic review of diagnosis text accuracy. In: Yang KH, editor. System evaluation guideline. Beijing: People’s Medical Publishing House; 2010. p. 191–5.Google Scholar
  29. 29.
    Zhang TS, Zhong WZ. Meta-DiSc software in meta-analysis of diagnostic test. J Evid Based Med. 2008;8:97–108.Google Scholar
  30. 30.
    Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327:557–60.CrossRefGoogle Scholar
  33. 33.
    Bowden J, Tierney JF, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Liu PL, Tang SS. Contrast enhanced ultrasound and contrast enhanced CT for diagnosis of focal pancreas lesions: a meta-analysis. Chin J Med Image Technol. 2011;27:2265–9.Google Scholar
  35. 35.
    Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046–55.CrossRefPubMedGoogle Scholar
  36. 36.
    Higgins JPT, Green S (editors). (2011). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions Version 5.1.0(updated March 2011). The Cochrane Collaboration. Available from
  37. 37.
    Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol. 2006;187:271–81.CrossRefPubMedGoogle Scholar
  38. 38.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.CrossRefPubMedGoogle Scholar
  39. 39.
    Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care. Meta-Analysis in context. London: BMJ Publishing Group; 2001. p. 248–82.CrossRefGoogle Scholar
  40. 40.
    Jaeschke R, Guyatt G, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, editors. Users’ guides to the medical literature. A manual for evidence-based clinical practice. Chicago: AMA Press; 2002. p. 121–40.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xiaoyan Zhang
    • 1
  • Yun Zhang
    • 1
  • Yunqiang Nie
    • 2
  • Shoufeng Wang
    • 1
  • Yanlin Chen
    • 3
  • Dezhong Sun
    • 3
  1. 1.Department of Medicine OncologyLinyi City People’s HospitalLinyiChina
  2. 2.Department of Respiratory MedicineLinyi City People’s HospitalLinyiChina
  3. 3.Department of OtolaryngologyLinyi City People’s HospitalLinyiChina

Personalised recommendations